AbbVie (ABBV) on Solana

AbbVie has acquired the rights and manufacturing facilities for West Pharmaceutical Services' SmartDose 3.5 mL On Body Delivery System, a large-volume wearable injector platform designed for subcutaneous drug delivery. Financial terms of the deal were not disclosed. The transaction gives AbbVie direct ownership and control over a specialized on-body delivery platform that could support its existing injectable biologics pipeline, including therapies that require high-volume subcutaneous administration.

West Pharmaceutical is divesting the 3.5 mL SmartDose configuration to streamline its portfolio and redirect resources toward GLP-1-related devices and larger 10 mL wearable systems, which it views as higher-value growth segments. For AbbVie, internalizing this delivery technology removes a third-party dependency for a differentiated dosing format, potentially offering greater flexibility in how it packages and differentiates future drug-device combination products.

The House Select Committee on China, led by Representative John Moolenaar (R-MI), launched a bipartisan investigation into AbbVie on June 30, 2026, over concerns that clinical trials conducted in China may have benefited the country's military. Letters sent to the company demanded responses by July 17 on due diligence practices, data protection standards, and the vetting of trial sites. AbbVie declined to comment. The committee identified at least 17 AbbVie trial sites in Xinjiang—a region tied to Beijing's documented repression of Uyghur minorities—and 16 additional sites at military-affiliated medical facilities, raising concerns about both informed-consent lapses and potential intellectual property transfer to Chinese military forces.

AbbVie has sponsored or collaborated on more than 100 clinical studies in China since 2007. The investigation adds regulatory and reputational pressure to the company at a moment when Washington is intensifying scrutiny of U.S. biotech activity in China. Moolenaar is also sponsoring the Biotech Investment National Security Act, which would require national security reviews for U.S. biotechnology licensing deals, joint ventures, and equity investments involving Chinese entities—a legislative push that could affect how AbbVie and peers structure future research partnerships in the country.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of AbbVie's upadacitinib (RINVOQ) for adults and adolescents with severe alopecia areata (AA). The recommendation covers both the 15 mg and 30 mg doses, which met the primary endpoint of a Severity of Alopecia Tool (SALT) score ≤ 20 at week 24 in the Phase 3 UP-AA program — a two-study trial enrolling 1,399 participants aged 12 to 64 across 248 global sites. Both doses also significantly outperformed placebo on complete scalp hair regrowth (SALT = 0) at week 24, with a safety profile consistent with RINVOQ's existing approved indications.

A positive CHMP opinion is a formal recommendation to the European Commission, which will make the final binding decision in the coming months. If approved, RINVOQ would become a treatment option for severe AA patients in Europe — a condition with limited existing therapies — extending AbbVie's immunology franchise into another indication and broadening the drug's addressable market beyond its current approvals in rheumatoid arthritis, atopic dermatitis, and other inflammatory diseases.

AbbVie announced on June 22, 2026, that it will acquire Apogee Therapeutics for $135.11 per share in cash, representing a total equity value of approximately $10.9 billion. The deal, which received unanimous board approval from both companies, is expected to close in Q3 2026 subject to customary regulatory and Apogee shareholder approvals.

The acquisition expands AbbVie's immunology pipeline with Apogee's clinical-stage candidates targeting inflammatory and immunological diseases including asthma and atopic dermatitis, strengthening its position in the respiratory space. The move is part of AbbVie's broader post-Humira M&A strategy to build out its next generation of blockbuster therapies.

AbbVie has secured two European Commission label expansions targeting pediatric populations: Skyrizi (risankizumab) was cleared for children with moderate to severe plaque psoriasis, and Maviret became the only therapy approved in the EU for both acute and chronic hepatitis C from age three. The additions open earlier treatment windows in immunology and virology, broadening addressable patient populations in both segments.

Analysts view the pediatric approvals as incremental rather than transformative, with the more significant near-term catalyst being AbbVie's $10.9 billion acquisition of Apogee Therapeutics, which adds atopic dermatitis and asthma assets to complement Skyrizi's existing immunology portfolio. The company's longer-term growth narrative rests on whether immunology and oncology expansion can offset ongoing Humira biosimilar erosion; projections through 2029 target $79.0 billion in revenue at roughly 7.9% annual growth, with earnings expected to rise sharply as R&D and acquisition costs normalize.